Definition, Diagnostic Criteria & Classification

Question	Answer
1. Define Systemic Juvenile Idiopathic Arthritis (sJIA) according to ILAR criteria.	Under International League of Associations for Rheumatology (ILAR) classification, sJIA is defined as: - Arthritis in $\ge 1$ joint accompanied or preceded by documented daily quotidian fever of at least 2 weeks' duration (spiking daily for at least 3 consecutive days), PLUS - At least one of the following four systemic features: 1) Evanescent (non-fixed) salmon-pink erythematous rash. 2) Generalized lymph node enlargement. 3) Hepatomegaly and/or splenomegaly. 4) Serositis (pericarditis, pleuritis, or peritonitis). - Exclusions: Psoriasis or history of psoriasis in patient or first-degree relative; HLA-B27 positivity in a male after 6th birthday; ankylosing spondylitis, enthesitis-related arthritis, reactive arthritis, or acute anterior uveitis in a first-degree relative; presence of IgM rheumatoid factor on 2 occasions 3 months apart.
2. What are the 2019 provisional PRINTO/EULAR classification criteria for sJIA, and how do they differ from ILAR?	The 2019 Pediatric Rheumatology International Trials Organization (PRINTO) criteria address the major flaw in ILAR: children presenting with severe systemic inflammation before overt arthritis develops. - Criteria: Fever of unknown origin spiking daily for $\ge 3$ consecutive days over $>2$ weeks, PLUS at least two of: 1) Evanescent erythematous rash. 2) Arthritis. 3) Generalized lymphadenopathy and/or hepatomegaly/splenomegaly. 4) Serositis. 5) Arthralgia lasting $\ge 2$ weeks (in the absence of arthritis). 6) Marked leukocytosis ($\ge 15,000/\mu\text{L}$) with neutrophilia, and elevated acute phase reactants (ferritin, CRP, ESR). - Key Departure: Arthritis is no longer mandatory at initial diagnosis if other hallmark features are present!
3. Describe the characteristic fever curve and rash of sJIA.	- Fever Pattern: High-spiking quotidian fever occurring once (or twice) daily, typically in late afternoon or evening, spiking to $\ge 39^\circ\text{C}$ ($\ge 102.2^\circ\text{F}$) and returning to normal baseline ($37^\circ\text{C}$) or subnormal levels between spikes. Child often looks toxic during fever spikes but remarkably playful and active when afebrile. - Rash: Classic evanescent, salmon-pink, non-pruritic, macular or maculopapular rash, migratory in distribution, prominent on trunk and proximal extremities, which waxes and wanes precisely synchronously with fever spikes and shows the Koebner phenomenon (linear wheals induced by mechanical skin stroking).
4. What are the 2016 EULAR/ACR/PRINTO diagnostic criteria for Macrophage Activation Syndrome (MAS) in sJIA?	In a child with established or suspected sJIA, MAS is diagnosed if there is a Fever, PLUS: - Serum Ferritin $> 684\text{ ng/mL}$, PLUS - Any two of the following four laboratory criteria: 1) Thrombocytopenia: Platelet count $\le 181,000/\mu\text{L}$ (or sudden precipitous drop from high baseline). 2) Hypertransaminasemia: Serum AST $> 48\text{ U/L}$. 3) Hypertriglyceridemia: Fasting triglycerides $> 156\text{ mg/dL}$. 4) Hypofibrinogenemia: Serum fibrinogen $\le 360\text{ mg/dL}$.
5. VIVA TRAP: Can a platelet count of 220,000/uL be abnormal in a child with suspected sJIA developing MAS?	YES, ABSOLUTELY. Active sJIA typically presents with massive reactive thrombocytosis (platelets often $600,000 - 1,000,000/\mu\text{L}$ driven by IL-6). A sudden drop from $800,000$ to $220,000/\mu\text{L}$ represents an alarming $>70\%$ consumptive drop indicating hemophagocytosis and impending MAS, even though $220,000/\mu\text{L}$ falls within the conventional laboratory reference range!

Pathophysiology & Complications

Question	Answer
6. Explain why sJIA is considered an "Autoinflammatory" rather than an "Autoimmune" disorder.	- Autoimmune diseases (e.g., SLE, pJIA): Driven by adaptive immunity (autoantibodies, autoreactive T and B cells, MHC class II linkage, female predominance). - Autoinflammatory diseases (sJIA): Driven by aberrant activation of the innate immune system without autoantibodies or antigen-specific T cells. - Danger signals (DAMPs like S100A8/A9 and S100A12 / calprotectin) bind TLR4, triggering NLRP3 inflammasome activation in monocytes and neutrophils, culminating in massive secretion of proactive cytokines: Interleukin-1$\beta$ (IL-1$\beta$), Interleukin-18 (IL-18), and Interleukin-6 (IL-6).
7. Detail the molecular pathophysiology of Macrophage Activation Syndrome (MAS).	- MAS is a secondary form of Hemophagocytic Lymphohistiocytosis (HLH). - Triggered by viral infections (EBV, CMV), medication switches, or uncontrolled disease. - Underpinning defect: Impaired cytotoxic lymphocyte (CD8+ T-cells and NK cells) function with defective perforin-granzyme granule-mediated apoptosis. - Inability to lyse antigen-presenting cells leads to sustained, uncontrolled antigen presentation, hypersecretion of Interferon-gamma (IFN-$\gamma$), and hyperactivation of tissue macrophages/histiocytes. - Activated macrophages infiltrate bone marrow, liver, and spleen, uncontrollably phagocytosing erythrocytes, platelets, and leukocytes (hemophagocytosis), releasing ferritin, plasminogen activator (fibrinolysis), and cytokines.
8. VIVA TRAP: Explain the "ESR-CRP Paradox" in early MAS.	In active sJIA, both ESR and CRP are sky-high ($ESR > 80\text{ mm/hr}$, $CRP > 100\text{ mg/L}$). When the child transitions into MAS, ESR paradoxically drops dramatically (often to $<20\text{ mm/hr}$) while CRP remains markedly elevated or rises further. Mechanism: ESR depends on erythrocyte rouleaux formation, which requires high circulating fibrinogen. In MAS, massive macrophage consumption and plasmin-mediated fibrinolysis consume fibrinogen (hypofibrinogenemia), abolishing rouleaux formation. CRP, synthesized directly by the liver under IL-6 stimulation, remains elevated. A falling ESR in a clinically deteriorating child with sJIA is an ominous diagnostic indicator of MAS, NOT improvement!
9. What is the role of serum Ferritin and Interleukin-18 in monitoring sJIA and MAS?	- Ferritin: In active sJIA without MAS, ferritin is moderately elevated ($200-1000\text{ ng/mL}$). In MAS, ferritin skyrockets, often $>5,000$ to $>50,000\text{ ng/mL}$, reflecting extreme macrophage secretory overload. - Interleukin-18 (IL-18): Extremely elevated in sJIA (mean $10,000 - 50,000\text{ pg/mL}$ vs $<300\text{ pg/mL}$ in other JIA subtypes). Persistent extreme elevation of IL-18 is a specific biomarker identifying patients at high risk of recurrent MAS and refractory lung disease.

Guidelines & Management Protocols (ACR 2021 Guidelines)

Question	Answer
10. Outline the initial pharmacological management of sJIA without MAS.	1) NSAIDs: Indomethacin ($2-3\text{ mg/kg/day}$) or Naproxen ($15-20\text{ mg/kg/day}$) may be trialed as temporary bridge for maximum 1-2 weeks; rarely provides sustained monotherapy control. 2) Biologic IL-1 / IL-6 Inhibitors (First-line): Modern ACR guidelines strongly recommend starting biologic therapy early ("window of opportunity"): - Anakinra (recombinant IL-1Ra): $1-2\text{ mg/kg/day}$ SC daily (titratable up to $4-8\text{ mg/kg/day}$). - Canakinumab (monoclonal anti-IL-1$\beta$): $4\text{ mg/kg}$ SC every 4 weeks. - Tocilizumab (humanized anti-IL-6R): $8\text{ mg/kg}$ IV q2w (for $\ge 30\text{ kg}$) or $12\text{ mg/kg}$ IV q2w (for $<30\text{ kg}$). 3) Systemic Glucocorticoids: Oral Prednisolone ($1-2\text{ mg/kg/day}$) or IV Methylprednisolone pulse ($30\text{ mg/kg/day}$, max $1000\text{ mg}$) for rapid systemic control while awaiting biologic access.
11. What is the emergency treatment protocol for Macrophage Activation Syndrome (MAS)?	MAS is a medical emergency with high mortality ($8-22\%$). Treatment must not be delayed for bone marrow biopsy: 1) High-Dose Pulse Methylprednisolone: $30\text{ mg/kg/day}$ IV (maximum $1000\text{ mg/day}$) infused over 1-2 hours for 3 consecutive days, followed by high-dose oral/IV prednisolone ($2-3\text{ mg/kg/day}$ divided q6h). 2) Calcineurin Inhibitor: Cyclosporine A (CsA) $3-5\text{ mg/kg/day}$ IV or orally divided q12h (target trough level $150-250\text{ ng/mL}$) added immediately if incomplete response within 24-48 hours. 3) High-Dose Interleukin-1 Blockade: Anakinra at high doses ($5-10\text{ mg/kg/day}$ IV or SC divided q6-8h). 4) Refractory MAS: Emapalumab (monoclonal antibody targeting IFN-$\gamma$) or Etoposide ($50-100\text{ mg/m}^2$).
12. What is sJIA-associated Lung Disease (sJIA-LD), and what are its risk factors?	- Emerging life-threatening complication characterized by pulmonary alveolar proteinosis (PAP), endogenous lipoid pneumonia, and pulmonary arterial hypertension. - Presentation: Finger clubbing, persistent hypoxemia, exertional dyspnea, and atypical rashes. - Associations/Triggers: Strongly associated with young age ($<2$ years), recurrent MAS, extreme IL-18 elevation, and adverse drug reactions (DRESS-like hypersensitivity) to IL-1 and IL-6 inhibitors.

VIVA TRAPs & Counter-Questions

Question	Answer
13. VIVA TRAP: A 5-year-old with daily high-spiking fevers, salmon rash, and arthritis has an ANA titer of 1:640 and RF positive. Is this sJIA?	NO. This diagnosis CANNOT be classified as sJIA under ILAR criteria. Under ILAR criteria, the presence of IgM Rheumatoid Factor on two occasions 3 months apart is an absolute exclusion criterion for sJIA. Furthermore, ANA is typically negative in true sJIA ($<10\%$). High-titer ANA and positive RF in a child with fever and arthritis strongly point toward Pediatric Systemic Lupus Erythematosus (pSLE), an overlap connective tissue disease, or Polyarticular RF-positive JIA!
14. Counter-Question Chain: "What are the common mimics of sJIA presenting with Prolonged Fever and High Inflammatory Markers? How do you exclude them before starting high-dose steroids?"	1) Infections: Occult bacteremia, infective endocarditis, osteomyelitis/septic arthritis, Bartonella (cat scratch), brucellosis, tuberculosis. - Exclusion: Multiple blood cultures, echocardiography, bone scan/MRI, TB IGRA/Mantoux. 2) Malignancy: Acute Lymphoblastic Leukemia (ALL) and Neuroblastoma. - Exclusion: Complete blood count with peripheral smear, bone marrow aspiration/biopsy (MANDATORY before steroids if any cytopenia or atypical bone pain is present, as steroids lyse blasts and make subsequent leukemia diagnosis treacherous!), spot urine catecholamines (VMA/HVA), imaging. 3) Vasculitis / Autoinflammatory: Kawasaki disease, polyarteritis nodosa (PAN), Familial Mediterranean Fever (FMF).
15. Counter-Question Chain: "Why is bone marrow biopsy performed in suspected MAS if criteria are already met clinically?"	Bone marrow examination is performed not to confirm MAS (since hemophagocytosis on marrow aspirate has poor sensitivity early in disease and is not required by 2016 criteria), but primarily to rule out underlying Acute Lymphoblastic Leukemia (ALL), lymphoma, or leishmaniasis which can trigger secondary HLH or mimic MAS, and whose management would be fundamentally compromised by blind immunosuppression!